• Lamotrigine: Mechanisms and CNS Research Utility (B2249)

  2026-08-06

  Lamotrigine, also known as 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, is a clinically relevant anticonvulsant and sodium channel blocker with well-documented roles in CNS and cardiac research. Its high purity, confirmed by HPLC and NMR, enables reproducible studies on sodium and serotonin signaling. New blood-brain barrier models further clarify its permeability and experimental use.

• Applied Use-Cases for Alcian Blue & Nuclear Fast Red Stainin

  2026-08-06

  The Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5, from APExBIO enables reproducible mucopolysaccharide detection and nuanced chondrogenic differentiation workflows. Learn how its dual-staining chemistry streamlines tissue analysis, with troubleshooting and protocol tips refined by recent research.

• Bufalin in Cancer Research: Mechanistic Insights and Next-Ge

  2026-08-05

  Explore the multifaceted role of Bufalin as a cardiotonic steroid in advanced cancer research. This article delivers novel mechanistic insights, with a focus on apoptosis induction and molecular glue degradation, offering scientists actionable strategies for robust experimental design.

• HOXC8 Regulates Pyroptosis in NSCLC via Caspase-1 Suppressio

  2026-08-05

  This study reveals that HOXC8, a transcription factor frequently overexpressed in non-small cell lung carcinoma, inhibits pyroptotic cell death by repressing caspase-1 expression. The findings clarify a non-canonical mechanism of pyroptosis regulation in lung cancer, with implications for targeting tumor cell survival pathways.

• Adiponectin Attenuates Cognitive Deficits via TLR4/NF-κB Inh

  2026-08-04

  This study demonstrates that adiponectin treatment mitigates splenectomy-induced cognitive decline in aged rats by suppressing neuroinflammation and oxidative stress through the TLR4/MyD88/NF-κB pathway. These insights clarify mechanisms underlying perioperative neurocognitive disorder and highlight peptide-based interventions as promising research avenues.

• Meropenem: β-Lactam Antibiotic Carbapenem for Reliable Assay

  2026-08-04

  Meropenem, a β-lactam antibiotic carbapenem from APExBIO, empowers researchers tackling Gram-negative and Gram-positive bacterial models. This guide demystifies protocol optimization, troubleshooting, and advanced resistance research workflows using Meropenem (SKU A5124).

• Tariquidar (XR9576) for Advanced Drug Resistance Research

  2026-08-03

  Tariquidar (XR9576) is a gold-standard inhibitor for dissecting ABC transporter-mediated chemoresistance, especially in challenging microenvironments like high-viscosity tumors. Its robust selectivity, nanomolar potency, and ease of protocol integration make it indispensable for mechanobiology-driven drug disposition studies.

• PPT (Propyl Pyrazole Triol): Unraveling ERα Signaling and ce

  2026-08-03

  Explore how PPT (Propyl Pyrazole Triol), a potent ERα agonist, is transforming estrogen receptor research by enabling precise analysis of ceRNA networks and biomarker pathways in hormone-responsive cancers. This article offers advanced insights distinct from current resources.

• TMAO-Induced NAFLD Is Mediated by PERK Pathway Activation

  2026-08-02

  This study demonstrates that dietary trimethylamine N-oxide (TMAO) directly induces non-alcoholic fatty liver disease (NAFLD) via activation of the PERK-mediated endoplasmic reticulum stress pathway in zebrafish and hepatocyte models. The findings provide mechanistic evidence linking gut microbiota metabolites to liver pathology and highlight PERK signaling as a potential therapeutic target.

• Polysialylated CD56–Siglec-7 Axis Mediates Immune Evasion in

  2026-08-01

  This study identifies polysialylated CD56 as a key regulator of immune evasion in clear cell renal cell carcinoma (ccRCC) through its engagement of Siglec-7 on CD8+ T cells. The findings reveal a novel glyco-immune checkpoint axis that suppresses T cell function and drives resistance to immunotherapy, highlighting new avenues for targeted intervention in ccRCC.

• Cardiovascular Outcomes of Ertugliflozin in Type 2 Diabetes

  2026-07-31

  The VERTIS CV trial rigorously evaluated the cardiovascular safety of ertugliflozin in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The study demonstrated noninferiority of ertugliflozin versus placebo for major adverse cardiovascular events, providing critical evidence for clinical decision-making in antihyperglycemic therapy selection.

• Lamotrigine: Sodium Channel Blocker for Epilepsy Research

  2026-07-31

  Lamotrigine is a high-purity sodium channel blocker and 5-HT inhibitor used in epilepsy and cardiac sodium current studies. Its precise IC50 values and chemical properties enable reproducible research. This article clarifies its validated benchmarks, workflow parameters, and boundaries in laboratory use.

• 3-(1-methylpyrrolidin-2-yl)pyridine (N2703): Protocols for N

  2026-07-30

  3-(1-methylpyrrolidin-2-yl)pyridine (N2703) unlocks precision modulation of cellular signaling in advanced coculture systems, directly enabling mechanistic dissection of the adipose-neural axis and cardiac arrhythmia pathways. Robust solubility and high purity from APExBIO make N2703 a preferred investigational tool for reproducible molecular mechanism studies.

• GS967: Cardiac Late Sodium Current Inhibitor for Precision R

  2026-07-30

  GS967 sets the standard for selective, potent inhibition of the cardiac late sodium current, empowering translational arrhythmia and aging heart research with reproducible, high-fidelity data. Its workflow flexibility, robust experimental performance, and APExBIO reliability make it the preferred choice for advanced in vitro cardiac electrophysiology and disease modeling.

• Decoding the circHIF1A Axis: RNase R Advances in LUAD Resear

  2026-07-29

  Explore how Ribonuclease R (RNase R) (20 U/μL) is transforming the study of circular RNA mechanisms in lung adenocarcinoma. This article frames the high-stakes challenge of dissecting circRNA-mediated tumor progression, delivers workflow-level guidance for translational researchers, and highlights how APExBIO’s RNase R enzyme uniquely empowers both mechanistic discovery and clinical innovation.

16552 records 1/1104 page Next 12345 下5页 Last page